An estimated 130,000-160,000 infections occur in infants and young children each year, despite progress in scaling up ART for pregnant and lactating people with HIV infection and ARV prophylaxis for their infants. Gaps in prevention strategies, especially during the breastfeeding period when roughly 50% of transmission occurs, have left infants vulnerable. As a discreet, safe and long-acting intervention, bNAbs hold the potential to close gaps in current strategies and to reduce infant infections as an adjunct to, or in place of, ARVs - supporting the elimination agenda. At the IAS2023 conference in Brisbane, a task force was launched to advance this promising prevention strategy, with more than 100 experts and community representatives from 44 different organizations signing on. This session will officially launch the action plan developed by the task force, outlining cross-cutting priority actions to accelerate a bNAbs indication for use in peri- and post-natal prophylaxis (PNP).